Your browser doesn't support javascript.
loading
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Drilon, Alexander; Horan, Joshua C; Tangpeerachaikul, Anupong; Besse, Benjamin; Ou, Sai-Hong Ignatius; Gadgeel, Shirish M; Camidge, D Ross; van der Wekken, Anthonie J; Nguyen-Phuong, Linh; Acker, Adam; Keddy, Clare; Nicholson, Katelyn S; Yoda, Satoshi; Mente, Scot; Sun, Yuting; Soglia, John R; Kohl, Nancy E; Porter, James R; Shair, Matthew D; Zhu, Viola; Davare, Monika A; Hata, Aaron N; Pelish, Henry E; Lin, Jessica J.
Afiliação
  • Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Horan JC; Nuvalent, Inc., Cambridge, Massachusetts.
  • Tangpeerachaikul A; Nuvalent, Inc., Cambridge, Massachusetts.
  • Besse B; Institut Gustave Roussy, Villejuif, France.
  • Ou SI; University of California Irvine Medical Center, Orange, California.
  • Gadgeel SM; Henry Ford Cancer Institute, Detroit, Michigan.
  • Camidge DR; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado.
  • van der Wekken AJ; University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Nguyen-Phuong L; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
  • Acker A; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
  • Keddy C; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
  • Nicholson KS; Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon.
  • Yoda S; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
  • Mente S; Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon.
  • Sun Y; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
  • Soglia JR; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Kohl NE; Nuvalent, Inc., Cambridge, Massachusetts.
  • Porter JR; Nuvalent, Inc., Cambridge, Massachusetts.
  • Shair MD; Nuvalent, Inc., Cambridge, Massachusetts.
  • Zhu V; Nuvalent, Inc., Cambridge, Massachusetts.
  • Davare MA; Kohl Consulting, Wellesley, Massachusetts.
  • Hata AN; Nuvalent, Inc., Cambridge, Massachusetts.
  • Pelish HE; Nuvalent, Inc., Cambridge, Massachusetts.
  • Lin JJ; Nuvalent, Inc., Cambridge, Massachusetts.
Cancer Discov ; 13(3): 598-615, 2023 03 01.
Article em En | MEDLINE | ID: mdl-36511802
SIGNIFICANCE: The combined preclinical features of NVL-520 that include potent targeting of ROS1 and diverse ROS1 resistance mutations, high selectivity for ROS1 G2032R over TRK, and brain penetration mark the development of a distinct ROS1 TKI with the potential to surpass the limitations of earlier-generation TKIs for ROS1 fusion-positive patients. This article is highlighted in the In This Issue feature, p. 517.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article